Volume 44, Issue 1 pp. 55-57
Full Access

Salivary excretion of mexiletine after bolus intravenous administration in rats

SADAO NAGASAKO

SADAO NAGASAKO

Department of Pharmacy, Shimane Medical University Hospital, 89-1, Enya-cho, Izumo 693, Japan

Search for more papers by this author
MASAKAZU HAYASHIBARA

MASAKAZU HAYASHIBARA

Department of Pharmacy, Shimane Medical University Hospital, 89-1, Enya-cho, Izumo 693, Japan

Search for more papers by this author
YOSHIHIRO KATAGIRI

YOSHIHIRO KATAGIRI

Department of Pharmacy, Shimane Medical University Hospital, 89-1, Enya-cho, Izumo 693, Japan

Search for more papers by this author
KIKUO IWAMOTO

Corresponding Author

KIKUO IWAMOTO

Department of Pharmacy, Shimane Medical University Hospital, 89-1, Enya-cho, Izumo 693, Japan

Department of Pharmacy, Shimane Medical University Hospital, 89-1 Enya-cho, Izumo 693, Japan.Search for more papers by this author
First published: January 1992
Citations: 7

Abstract

Abstract— Salivary excretion of mexiletine was investigated following bolus intravenous administration (10 mg kg−1) in rats. Parotid and mandibular saliva was collected separately by stimulating salivation with constant rate infusion of pilocarpine (3 mg kg−1 h−1). The mexiletine levels in blood plasma and parotid and mandibular saliva declined biexponentially with time in almost parallel fashion. Although the mexiletine levels in both types of saliva were lower than that in plasma, the drug level in parotid saliva was always higher than that in mandibular saliva. Significant correlations were observed when all data relating mexiletine concentration in plasma and saliva were included (P < 0·001). The saliva/plasma drug concentration ratios (S/P ratios) did not vary to a large extent (0·56 ± 0·10 for parotid saliva, 0·21 ± 0·06 for mandibular saliva), but there was a consistent tendency for the higher plasma drug levels in the distribution phase to produce relatively high S/P ratios for both parotid and mandibular saliva. Moreover, the plasma mexiletine levels calculated by the equation of Matin et al (1974) employing the observed values for the saliva drug level, saliva pH and free fraction of mexiletine in plasma were significantly higher than the observed drug levels. Therefore, it is suggested that the salivary excretion of mexiletine could not be explained quantitatively by simple, passive secretion based on pH-partition theory.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.